← back to search

Eri Kato

Hiroshima University · JP
Area of research
Cardiology and Cardiovascular Medicine · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Diabetes Treatment and Management, Heart Failure Treatment and Management, Acute Myocardial Infarction Research, and Pancreatic function and diabetes.
h-index
22
citations
12,771
works
101
NIH funding
primary concept
Medicine
email

Recent publications

Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis
European Heart Journal 2022cited by 94position: firstdoi
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
The Lancet Diabetes & Endocrinology 2019cited by 671position: middledoi
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
Circulation 2019cited by 559position: firstdoi
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
New England Journal of Medicine 2018cited by 6,242position: middledoi
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
The Lancet 2018cited by 2,784position: middledoi
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
American Heart Journal 2018cited by 182position: middledoi
<scp>DECLARE‐TIMI</scp> 58: Participants’ baseline characteristics
Diabetes Obesity and Metabolism 2018cited by 112position: middledoi
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial
Journal of the American Heart Association 2016cited by 280position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Marc S. Sabatine · Smart Material (Germany)7 papers (2018–2022)Stephen D. Wiviott · Brigham and Women's Hospital7 papers (2018–2022)Deepak L. Bhatt · Technische Universität Dresden6 papers (2018–2019)John Wilding · University of Liverpool6 papers (2018–2019)Avivit Cahn · Hadassah Medical Center6 papers (2018–2019)Darren K. McGuire · Saint Luke's Health System6 papers (2018–2019)Lawrence A. Leiter · St. Michael's Hospital6 papers (2018–2019)Ofri Mosenzon · Hadassah Medical Center6 papers (2018–2019)Marc P. Bonaca · Amsterdam University Medical Centers6 papers (2018–2022)Ingrid Gause‐Nilsson · AstraZeneca (Switzerland)5 papers (2018–2019)Peter A. Johansson · QIMR Berghofer Medical Research Institute5 papers (2018–2019)Anna Maria Langkilde · AstraZeneca (Brazil)4 papers (2018–2019)Michael G. Silverman · Harvard University4 papers (2018–2019)Thomas A. Zelniker · Thrombolysis in Myocardial Infarction Study Group4 papers (2018–2019)Itamar Raz · Thrombolysis in Myocardial Infarction Study Group4 papers (2018–2019)Sabina A. Murphy · Boise Bible College4 papers (2016–2019)Christian T. Ruff · Brigham and Women's Hospital3 papers (2016–2019)Julia Kuder · Harvard University2 papers (2018–2019)Eugene Braunwald · Mass General Brigham2 papers (2016–2022)Erica L. Goodrich · Harvard University2 papers (2018–2019)